| Title |
The Future of Osteoarthritis Therapeutics: Targeted Pharmacological Therapy
|
|---|---|
| Published in |
Current Rheumatology Reports, September 2013
|
| DOI | 10.1007/s11926-013-0364-9 |
| Pubmed ID | |
| Authors |
A. Mobasheri |
| Abstract |
Osteoarthritis (OA) is one of the most common forms of degenerative joint disease and a major cause of pain and disability affecting the aging population. It is estimated that more than 20 million Americans and 35 to 40 million Europeans suffer from OA. Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are the only therapeutic treatment options for OA. Effective pharmacotherapy for OA, capable of restoring the original structure and function of damaged cartilage and other synovial tissue, is urgently needed, and research into such disease-modifying osteoarthritis drugs (DMOADs) is in progress. This is the first of three reviews focusing on OA therapeutics. This paper provides an overview of current research into potential structure-modifying drugs and more appropriately targeted pharmacological therapy. The challenges and opportunities in this area of research and development are reviewed, covering the most up-to-date initiatives, trends, and topics. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ukraine | 2 | 20% |
| Russia | 1 | 10% |
| United States | 1 | 10% |
| Unknown | 6 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 90% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 137 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 23 | 17% |
| Student > Bachelor | 22 | 16% |
| Student > Master | 16 | 12% |
| Researcher | 14 | 10% |
| Student > Doctoral Student | 7 | 5% |
| Other | 25 | 18% |
| Unknown | 31 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 27% |
| Biochemistry, Genetics and Molecular Biology | 15 | 11% |
| Agricultural and Biological Sciences | 14 | 10% |
| Engineering | 5 | 4% |
| Neuroscience | 4 | 3% |
| Other | 21 | 15% |
| Unknown | 42 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2016.
All research outputs
#1,910,936
of 22,723,682 outputs
Outputs from Current Rheumatology Reports
#61
of 707 outputs
Outputs of similar age
#18,288
of 203,072 outputs
Outputs of similar age from Current Rheumatology Reports
#3
of 15 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 707 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.